Millions of Americans take statins to manage high cholesterol and reduce their risk of cardiovascular disease, making the potential side effects of these widely-prescribed drugs a critical area of ongoing research. A new study published November 11 in *Cardiovascular Diabetology* explores a complex link between statin use and the development of type 2 diabetes, prompting a closer look at the interplay between cholesterol levels and metabolic health. Researchers are now investigating whether the diabetes risk stems from the medication itself, or from the resulting reduction in LDL cholesterol [[1]].
Individuals taking statins to lower cholesterol may face an increased risk of developing type 2 diabetes, but the relationship is complex, according to a new study published November 11 in Cardiovascular Diabetology. Understanding the interplay between cholesterol levels, statin use, and diabetes risk is crucial for both patients and healthcare providers as cardiovascular disease and diabetes often coexist.
Researchers at the University of Federico II in Naples, Italy, and colleagues investigated whether the increased diabetes risk associated with statins is due to the drugs themselves or the resulting lower levels of low-density lipoprotein (LDL) cholesterol. Previous genetic studies have indicated that people with naturally low LDL-C levels have a higher predisposition to type 2 diabetes, raising questions about the underlying cause of the observed risk.
The study followed 13,674 individuals, aged 19 to 90, without a prior diagnosis of diabetes for nearly six years. During the study period, 1,819 participants (13%) developed type 2 diabetes. Participants were categorized into four groups based on their initial LDL-C levels: less than 0.84 g/L, 0.84 to 1.07 g/L, 1.07 to 1.31 g/L, and greater than 1.31 g/L.
The findings revealed an inverse relationship between LDL-C levels and diabetes risk. The incidence of diabetes was 27.6 cases per 1,000 person-years in the group with the lowest LDL-C levels, decreasing to 17.4, 13.5, and 8.4 cases per 1,000 person-years in subsequent groups with higher LDL-C levels. This suggests that lower LDL-C is associated with a greater risk of developing type 2 diabetes.
However, the study also showed that statin use, regardless of LDL-C levels, was independently associated with an elevated diabetes risk. The risk of diabetes was increased by 75% in those taking statins with the lowest LDL-C levels, 63% in the second quartile, 54% in the third, and 2.4 times higher in those with the highest LDL-C levels who were also on statins.
These results indicate that statins may increase diabetes risk through two distinct mechanisms: by lowering LDL-C levels and through a separate, statin-specific effect. Researchers suggest that LDL-cholesterol levels could potentially serve as a biomarker for assessing type 2 diabetes risk. The study underscores the need for a nuanced understanding of the benefits and risks associated with statin therapy, particularly in individuals already predisposed to diabetes.
